Trial Profile
A Phase 1, Open-label, Randomized Crossover Study, in Healthy Adult Subjects to Assess the Relative Oral Bioavailability of a Single 500-mg Dose of JNJ-53718678 Administered as (an) Oral Concept Formulation(s) Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of (an) Oral Concept Formulation(s)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Mar 2020
Price :
$35
*
At a glance
- Drugs Rilematovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 09 Mar 2020 Status changed from recruiting to completed.
- 29 Oct 2019 Planned End Date changed from 1 Nov 2019 to 1 Jan 2020.
- 16 Apr 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Nov 2019.